The main focus of the research group is in translational research in gynaecological cancers. In particular biomarker discovery and development (specifically immunological markers) in ovarian and endometrial cancers. The biomarkers are now in the process of being tested for diagnosis and surgical prognosis. The concept of predicting surgical outcome in ovarian cancer is a step in developing personalised medicine and providing patients with best care possible.
Recent advances in oncolgy have improved survival in patients with cancer but research into surgery may have additional benefits for the patient. Clinical research into optimal treatment of cervival preinvasive lesions has been a focus. We have shown that clear margins of resection has a significant effect on reducing risk of recurrence from preinvasive disease.
et al., 2022, Study protocol for a randomised controlled trial on the use of intra-operative Ultrasound Guided Laparoscopic Ovarian Cystectomy (UGLOC) as a method of fertility preservation in the management of benign ovarian cysts, Bmj Open, Vol:12, ISSN:2044-6055
et al., 2022, The use of biomarkers to stratify surgical care in women with ovarian cancer Scientific Impact Paper No. 69[March] 2022, Bjog-an International Journal of Obstetrics and Gynaecology, ISSN:1470-0328
et al., 2022, British Gynaecological Cancer Society Recommendations for Women With Gynecological Cancer Who Received Non-standard Care During the COVID-19 Pandemic, Obstetrical & Gynecological Survey, Vol:77, ISSN:0029-7828, Pages:156-157
et al., 2022, British Gynaecological Cancer Society Recommendations for Women With Gynecological Cancer Who Received Non-standard Care During the COVID-19 Pandemic, Obstetrical &amp; Gynecological Survey, Vol:77, ISSN:0029-7828, Pages:156-157
et al., 2022, Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer (vol 385, pg 2123, 2021), New England Journal of Medicine, Vol:386, ISSN:0028-4793, Pages:704-704